Supplemental Methods
Patients. We evaluated the impact of plasma HGF levels on overall survival ( Written informed consent was obtained from all protocol patients before initiation of any study procedures.
Biomarker analysis. Worsening hepatic function was defined as an increase in CTP score by at least 1 point within 3 months. To delineate the impact of the therapeutic intervention on biomarker association, we also measured pretreatment plasma HGF levels in 101 patients with HCC who underwent surgical treatments, 86 of whom presented with underlying cirrhosis, at Fundeni Clinical Institute, Romania (Table S4 ). Plasma analysis of HGF concentration was carried out in duplicate in the CLIA-certified facility of the Steele Laboratories at MGH, using ELISA kits (R&D Systems).
In the radiotherapy study, progression-free survival (PFS) and overall survival (OS) were calculated from the first day of treatment. OS time was censored at the date of last follow-up for of patients still alive. PFS was measured until the earliest of any documented recurrence or death, and otherwise censored at the date of last follow-up. In the surgical study, we defined diseasefree survival (DFS) as the time from surgery to any local tumor recurrence or distant-organ metastasis, and OS as the period of time from surgery until death or last follow-up.
Statistical analysis.
Wilcoxon rank-sum test was used to compare the distribution of pretreatment plasma HGF levels between patients with and without an increase in CTP. Wilcoxon signed-rank test was used to assess the change in plasma HGF levels between baseline and day 8 or day 15. The Kaplan-Meier method was used to estimate 2-year OS, and the logrank test was used to compare OS and PFS between patients with high and low pretreatment plasma HGF.
Data analysis was performed using SAS 9.4 (SAS Inst Inc, Cary, NC) and R 3.3.1 (R Foundation), with p-values based on a two-sided hypothesis. Circulating plasma HGF correlation with DFS or OS in patients undergoing surgical treatment was tested using Wald test in univariate Cox regression analysis, using log-transformed covariates. Comparison of biomarker levels after stratifying patients based on presence of cirrhosis was performed using exact Wilcoxon test, and correlation with Model for End-stage Liver Disease (MELD) score was evaluated using Spearman rank correlation test.
